267 related articles for article (PubMed ID: 26735339)
1. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Terranova-Barberio M; Roca MS; Zotti AI; Leone A; Bruzzese F; Vitagliano C; Scogliamiglio G; Russo D; D'Angelo G; Franco R; Budillon A; Di Gennaro E
Oncotarget; 2016 Feb; 7(7):7715-31. PubMed ID: 26735339
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
Di Gennaro E; Piro G; Chianese MI; Franco R; Di Cintio A; Moccia T; Luciano A; de Ruggiero I; Bruzzese F; Avallone A; Arra C; Budillon A
Br J Cancer; 2010 Nov; 103(11):1680-91. PubMed ID: 21045833
[TBL] [Abstract][Full Text] [Related]
3. Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Zhang SH; Zhang H; He HW; Li L; Li XQ; Zhang YP; Shao RG
Cancer Chemother Pharmacol; 2013 Oct; 72(4):777-88. PubMed ID: 23975242
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.
Puppin C; Puglisi F; Pandolfi M; Di Loreto C; Damante G
Oncol Rep; 2011 Aug; 26(2):309-14. PubMed ID: 21617864
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
6. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
7. Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells.
Chen YR; Tsou B; Hu S; Ma H; Liu X; Yen Y; Ann DK
Oncotarget; 2016 Jan; 7(2):1984-99. PubMed ID: 26675256
[TBL] [Abstract][Full Text] [Related]
8. 5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
Schwartz EL; Baptiste N; Megati S; Wadler S; Otter BA
Cancer Res; 1995 Aug; 55(16):3543-50. PubMed ID: 7627962
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.
Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q
J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483
[TBL] [Abstract][Full Text] [Related]
10. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation.
Jawed S; Kim B; Ottenhof T; Brown GM; Werstiuk ES; Niles LP
Eur J Pharmacol; 2007 Mar; 560(1):17-22. PubMed ID: 17303109
[TBL] [Abstract][Full Text] [Related]
11. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Fujimoto-Ouchi K; Tanaka Y; Tominaga T
Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Morita T; Matsuzaki A; Tokue A
Int J Cancer; 2001 May; 92(3):451-6. PubMed ID: 11291085
[TBL] [Abstract][Full Text] [Related]
13. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.
Blanquicett C; Gillespie GY; Nabors LB; Miller CR; Bharara S; Buchsbaum DJ; Diasio RB; Johnson MR
Mol Cancer Ther; 2002 Oct; 1(12):1139-45. PubMed ID: 12481438
[TBL] [Abstract][Full Text] [Related]
14. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
15. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?
Bonotto M; Bozza C; Di Loreto C; Osa EO; Poletto E; Puglisi F
Clin Breast Cancer; 2013 Jun; 13(3):167-72. PubMed ID: 23218471
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.
Terranova-Barberio M; Pecori B; Roca MS; Imbimbo S; Bruzzese F; Leone A; Muto P; Delrio P; Avallone A; Budillon A; Di Gennaro E
J Exp Clin Cancer Res; 2017 Dec; 36(1):177. PubMed ID: 29212503
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
[TBL] [Abstract][Full Text] [Related]
19. DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft.
Zheng MF; Shen SY; Huang WD
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1031-41. PubMed ID: 24043136
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]